Stock Ratings / Health Care / SGMT / dividends

APMD (47) WVE (32) GYRE (46) ANNX (40) ⌘ Pro Terminal →

Sagimet Biosciences Inc. (Series A) (SGMT) Dividend Safety Gauge & 10-Year DRIP Compounder

$10.43 -2.89% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $10.36

Sagimet Biosciences Inc. (Series A) (SGMT) carries a Roarable Rating of E (Strong Sell) with 34/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

📊 Historical Track Record Warning: Scores below 50 (34/100 · E) historically underperformed SPY in 71% of rolling 90-day windows →

ROARABLE E • RED ALERT Cap $735.7M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $10.36 (-0.71%)🧬 Dilution Drag (+2.48% YoY Shares)⚙️ Cash Engine: 7/20 (D-) • 0% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record Warning: Scores below 50 (34/100 · E) historically underperformed SPY in 71% of rolling 90-day windows (-8.7% avg 90D alpha vs SPY • 29.0% hit rate).

Audit Bucket Track Record →

RQD QUANT TACHOMETERRED ALERT • E

3-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw E · Rk D

Each axis scored 0–20

12M PRICE TARGET CONE-10.8% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for SGMT)Realized 20D OHLCV Swing Band: ±12.5%

Deterministic 5-Pillar Attribution (34/100 Composite)

🔍 WHY SGMT SCORES 34/100 (E) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: SEC 10-K Forensic Risk+10/20 pts (29% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 2/9

▲ #2 Bullish Driver: Macro Regime Fit+8/20 pts (24% of score)

FRED Regime × Technicals: 85% of 52W Range • RSI-14 at 53.2 (NEUTRAL RANGE)

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution4/20 pts (-16 pt drag)

Dilution Drag (+2.48% YoY Shares) & executive Form 4 sales trim 16 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade E$8.93-10.2% Next Q

Q2 (-2Q)

Grade E$8.02+19.5% Next Q

Q3 (-1Q)

Grade E$9.58+8.9% Next Q

Current

Grade E$10.43-8.7% Hist 90D α

Trajectory: E (26) → E (34)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a SGMT Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While SGMT currently carries a cautious 34/100 (E) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($9.93) and Max Pain ($10.95) forces dealer call-delta covering toward $12.02.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Dilution Drag (+2.48% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $SGMT• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “SGMT Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”

YES 34%NO 66%Trade / Inspect Odds →

CASH DIVIDEND + BUYBACK YIELD

0.6% Total Yield

0% Cash ($0.00/yr) + 0.6% Buybacks

PAYOUT SAFETY SPEEDOMETER

74/100 • REINVESTING IN GROWTH + BUYBACKS

FREE CASH FLOW PAYOUT RATIO

0% (100% Reinvested)

Retains cash flow for R&D and share repurchases

INTERACTIVE DRIP & SHAREHOLDER-YIELD COMPOUNDER (5.5% EST. ANNUAL)

$10,000 Compounded Over 10 Years → $17,081

Est. Year-10 Shareholder Yield: $102/yr

Starting Investment: $10,000

Compounding Horizon: 10 Years

$10.6K

Yr 1

$11.1K

Yr 2

$11.7K

Yr 3

$12.4K

Yr 4

$13.1K

Yr 5

$13.8K

Yr 6

$14.5K

Yr 7

$15.3K

Yr 8

$16.2K

Yr 9

$17.1K

Yr 10

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring SGMT)

✓Walkthrough of SGMT's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

SGMT // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +29.89%▲ ASCENDING CHANNEL

2026-10-30O $10.41H $10.53L $9.82C $10.43VOL 989.1K

RES: $13.38SUP: $7.75SMA50: $9.93SMA200: $7.50

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

SGMT Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 SGMT Butterfly Map → + Track SGMT →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on SGMT today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for SGMT. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for SGMT today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (SGMT)

Health Care Rank #837 of 1016 ⚔️ APMD vs SGMT Full Matrix →

1. Head-to-Head Health Care Peer Comparison (SGMT vs. APMD, WVE, GYRE, ANNX)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Sagimet Biosciences Inc. (Series A) (SGMT) ranks #837 by composite RQD confidence (34/100, grade E) and #395 by equity capitalization ($735.7M). Within this direct 5-issuer industry benchmark cohort, GYRE leads on earnings valuation at 72.3x trailing P/E, while GYRE leads on capital efficiency and profitability with 25.4% ROIC and 95.4% gross margin. APMD currently holds the highest overall quantitative score in the immediate peer group at 47/100 (D) compared with SGMT at 34/100 (E).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
SGMT ACTIVE Sagimet Biosciences Inc. (Series A)	E	34/100	—	—	-35.0%	-2.89%	$735.7M	Benchmark Subject
APMD Apnimed Inc.	D	47/100	—	—	—	-9.45%	$721.9M	/apmd-vs-sgmt →
WVE Wave Life Sciences Inc.	E	32/100	—	—	-35.0%	-0.28%	$715.9M	/wve-vs-sgmt →
GYRE Gyre Therapeutics Inc.	D	46/100	72.3x	95.4%	25.4%	-9.59%	$714.8M	/gyre-vs-sgmt →
ANNX Annexon Inc.	D-	40/100	—	—	-35.0%	-0.74%	$760.2M	/annx-vs-sgmt →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001400118

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Sagimet Biosciences Inc. (Series A) (SGMT) reported GAAP revenue of $0 (N/A vs. FY2024 revenue of $0 , and -100.0% cumulative change since FY2023) , GAAP net income of -$51.0M, operating cash flow of -$45.6M, and free cash flow of -$45.6M (-7.6% YoY). On the balance sheet, SGMT closed FY2025 with $116.5M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 2/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$0	-$51.0M	-$45.6M	-$45.6M	$116.5M	—
FY2024 (FY)	2024-12-31	$0	-$45.6M	-$42.4M	-$42.4M	$160.3M	—
FY2023 (FY)	2023-12-31	$2.0M	-$27.9M	-$23.8M	-$23.8M	—	—

3. SGMT Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is SGMT stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-01, Sagimet Biosciences Inc. (Series A) (NASDAQ: SGMT) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 34/100 at a spot price of $10.43 (-2.89% 1D, market cap $735.7M). Pillar breakdown: Fundamental Cash Engine 7/20, Institutional 13F & Options Flow 6/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 8/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, SGMT ranks #837 in composite RQD confidence.

How does SGMT compare to APMD and WVE in the Health Care sector?

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), SGMT carries a Roarable E (34/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, APMD (Apnimed Inc.) holds a D grade (47/100 RQD, P/E N/A, ROIC —, cap $721.9M) and WVE (Wave Life Sciences Inc.) posts a E grade (32/100 RQD, P/E N/A, ROIC -35.0%, cap $715.9M). Among the 5-stock peer group, GYRE leads on earnings multiple (72.3x) while GYRE leads on capital efficiency (25.4% ROIC).

What are the biggest fundamental strengths and SEC risk factors for SGMT?

Per SGMT's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001400118), Sagimet Biosciences Inc. (Series A) generated $0 in revenue, -$51.0M in net income, and -$45.6M in free cash flow against $116.5M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is SGMT trading relative to its 50-day, 200-day, and 52-week technical levels?

SGMT last traded at $10.43 (-2.89% on volume of 746,467 shares), positioning the stock +5.04% above its 50-day simple moving average ($9.93) and +39.07% above its 200-day simple moving average ($7.50). Across its 52-week range of $4.50 to $11.45, SGMT sits at the 85.3% percentile with a 14-day RSI of 53.2 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($9.13 to $11.73).

SGMT Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

Does SGMT pay a dividend and is it safe?

Sagimet Biosciences Inc. (Series A) (SGMT) offers a 0% cash dividend yield ($0.00 annualized) and 0.6% total shareholder yield including buybacks. Roarable rates its payout coverage as REINVESTING IN GROWTH + BUYBACKS.

Direct Sub-Reports: SGMT RQD Cockpit SGMT 12M Forecast SGMT Earnings & Move SGMT Dividends & DRIP SGMT Insiders & 13F SGMT Whale Options SGMT Profit Sankey SGMT News & Why